ArticleAnnals of epidemiology2018
Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014.
Article in Annals of epidemiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of Caveolin-1 Expression With Prostate Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study.Targeted oncology · 2019Trial
- Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?PloS one · 2019Trial
- Concurrent Management of Prostate Cancer and Perianal Fistula: A Case Report, Treatment Considerations, and Review of Literature.Case reports in urology · 2026Article
- Prostate cancer screening in the Middle East and North Africa: a cross-sectional study on current practices.JNCI cancer spectrum · 2025Article
- DNA methylation markers for risk of metastasis in a cohort of men with localized prostate cancer.Epigenetics · 2024Article
- Association between surgery treatment delays and survival outcomes in patients with esophageal cancer in Hebei, China.Frontiers in oncology · 2024Article
- Trends in prostate cancer incidence among Black men in the Caribbean and the United States.The Prostate · 2023Article
- Defining aggressive prostate cancer: a geospatial perspective.BMC cancer · 2023Article
- Exposure to statins post localized prostate cancer diagnosis and risk of metastasis among men who did not receive curative prostate cancer treatment.Cancer reports (Hoboken, N.J.) · 2023Article
- The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer.International journal of clinical oncology · 2023Article
- A Historical Misconception in Clinical Trials of Drugs for Cancer-Age Grouping.Journal of personalized medicine · 2022Article
- Increasing aggressive prostate cancer.The Canadian journal of urology · 2022Article
- Integrated analysis to identify the AC005154.6/hsa-miR-29c-3p/CCNL2 axis as a novel prognostic biomarker associated with immune infiltration in prostate cancer.Cancer cell international · 2022Article
- How competing risks affect the epidemiological relationship between vitamin D and prostate cancer incidence? A population-based study.Andrologia · 2022Article
- Uncovering interpretable potential confounders in electronic medical records.Nature communications · 2022Article
- Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now?Cancers · 2022Review
- Impact of cancer screening on metastasis: A prostate cancer case study.Journal of medical screening · 2021Article
- Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management.Cancers · 2021Review
- Cerebral Cavernous Malformation 1 Determines YAP/TAZ Signaling-Dependent Metastatic Hallmarks of Prostate Cancer Cells.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeCurrent literature shows different findings on the contemporary trends of distant-stage prostate cancer incidence, in part, due to low study population coverage and wide age groupings. This study aimed to examine the stage-specific incidence rates and trends of prostate cancer by age (5-year grouping), race, and ethnicity using nationwide cancer registry data.
methodsData on prostate cancer cases came from the 2004-2014 United States Cancer Statistics data set. We calculated stage-specific incidence and 95% confidence intervals by age (5-year age grouping), race, and ethnicity. To measure the changes in rates over time, we calculated annual percentage change (APC).
resultsWe identified 2,137,054 incident prostate cancers diagnosed during 2004-2014, with an age-adjusted incidence rate of 453.8 per 100,000. Distant-stage prostate cancer incidence significantly decreased during 2004-2010 (APC = -1.2) and increased during 2010-2014 (APC = 3.3). Significant increases in distant prostate cancer incidence also occurred in men aged older than or equal to 50 years except men aged 65-74 and older than or equal to 85 years, in men with white race (APC = 3.9), and non-Hispanic ethnicity (APC = 3.5).
conclusionsUsing data representing over 99% of U.S. population, we found that incidence rates of distant-stage prostate cancer significantly increased during 2010-2014 among men in certain ages, in white, and with non-Hispanic ethnicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.